#USA #New York #Gross Law Firm #Telix Pharmaceuticals #TLX

Important Notice for Telix Pharmaceuticals Shareholders

Are you a shareholder of Telix Pharmaceuticals Ltd. and purchased your shares during the class period from February 21, 2025, to August 28, 2025? If so, an important opportunity to protect your rights is available through The Gross Law Firm. Shareholders are encouraged to reach out prior to January 9, 2026, to discuss potential actions related to their investments. This advice comes due to pending allegations that the company misled investors regarding its prostate cancer therapeutic candidates and the quality of its supply chains.

Context of the Allegations

During the noted class period, Telix Pharmaceuticals allegedly issued misleading statements that drastically overestimated both the progress the company was making in treating prostate cancer and the reliability of its operational partners. Such misinformation raises significant concerns about the integrity of Telix’s business practices and the validity of its prospects. As a result, this announcement aims to ensure shareholders do not inadvertently overlook their legal options regarding any financial losses they may have incurred.

Importance of Acting Promptly

The deadline for filing claims and seeking lead plaintiff status is fast approaching on January 9, 2026. Shareholders should prioritize registration to familiarize themselves with the potential implications of this class action. By registering, you not only secure your place in the legal proceedings but also gain access to portfolio monitoring software that delivers vital updates throughout the case lifecycle. Participating in this initiative does not entail any cost or obligation for the shareholders.

The Role of The Gross Law Firm

The Gross Law Firm is a nationally recognized entity committed to safeguarding the interests of investors. Their mission encompasses the pursuit of accountability and transparency in corporate operations, particularly in response to any fraud or deceptive practices that could undermine investor trust. The firm emphasizes that the path to recovery does not necessitate appointment as a lead plaintiff, encouraging all affected shareholders to assess their situation and proceed accordingly.

Next Steps for Shareholders

To participate, shareholders should complete registration via the link provided within The Gross Law Firm's announcement. Doing so ensures that you receive timely notifications and can actively engage in the recovery process. By being proactive now, investors can safeguard their rights and potentially regain some of the losses tied to their investment in Telix Pharmaceuticals.

The financial landscape surrounding Telix Pharmaceuticals represents a significant case study in investor accountability and corporate ethics. It serves as a potent reminder for investors to remain vigilant and informed about the companies in which they invest. In navigating this challenging terrain, the support and guidance from specialized legal firms can provide crucial assistance in protecting shareholder interests.

For further inquiries or to initiate the registration process, reach out to The Gross Law Firm:

• - Address: 15 West 38th Street, 12th floor, New York, NY, 10018
• - Email: [email protected]
• - Phone: (646) 453-8903

Prepare to act swiftly as this is a pivotal moment for shareholders of Telix Pharmaceuticals. Stay informed and safeguard your investments with the right legal support.